Tetrabenazine in the treatment of Huntington’s disease

Tetrabenazine (TBZ), a catecholamine-depleting agent initially developed for the treatment of schizophrenia, when tested for other indications, has proven to be more useful for the treatment of a variety of hyperkinetic movement disorders. These disorders include neurological diseases characterized by abnormal involuntary movements such as chorea associated with Huntington’s disease, tics in Tourette’s syndrome, dyskinesias and dystonias in tardive dyskinesia, also primary dystonias and myoclonus. This review will include and discuss studies published during the period of 1960–2006 regarding the clinical efficacy and tolerability of TBZ in Huntington’s disease (HD). It will also review the chemistry, pharmacokinetics and dynamics of the drug and its mechanism of action compared to that of reserpine, the only similar compound. This review emphasizes the advantage of TBZ over dopamine-depleting compounds used in the treatment of chorea and reveals its clinical efficacy and side effects.

• Publication year

  2007

• Venue

  Neuropsychiatric Disease and Treatment

• Publication date

  2007-10-01

• Fields of study

  Medicine

• Identifiers
  PMID 19381278PMCID 2656291
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacological Options for the Treatment of Tourette’s Disorder

  2012cited by this paper
• Tetrabenazine as antichorea therapy in Huntington disease

  2006cited by this paper
• Tetrabenazine in the treatment of hyperkinetic movement disorders

  2006cited by this paper
• The pharmacokinetics of tetrabenazine and its hydroxy metabolite in patients treated for involuntary movement disorders

  2004cited by this paper
• Tetrabenazine Treatment in Movement Disorders

  2004cited by this paper
• Tetrabenazine Treatment for Huntington's Disease-Associated Chorea

  2002cited by this paper
• [Spasmodic torticollis and vertebral hemangioma].

  2001cited by this paper
• Repetitive administration of tetrabenazine induces irreversible changes in locomotion and morphology of the substantia nigra in rats.

  2001cited by this paper
• Pharmacologic treatment of tic disorders.

  2000cited by this paper
• Evaluation and Treatment of Dystonia

  2000cited by this paper
• The treatment of tardive dyskinesia and tardive dystonia.

  2000cited by this paper
• Blepharospasm and hemifacial spasm

  2000cited by this paper
• Tardive dyskinesia

  2000cited by this paper
• Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol.

  1999cited by this paper
• Managing Antipsychotic-Induced Acute and Tardive Dystonia

  1998cited by this paper
• Status dystonicus: the syndrome and its management.

  1998cited by this paper
• Clozapine versus placebo in Huntington’s disease: a double blind randomised comparative study

  1997cited by this paper
• Tardive tremor

  1997cited by this paper
• Long-term effects of tetrabenazine in hyperkinetic movement disorders

  1997cited by this paper
• Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter.

  1996cited by this paper
• Tetrabenazine as a cause of neuroleptic malignant syndrome

  1996cited by this paper
• Emotional and functional impact of DNA testing on patients with symptoms of Huntington's disease.

  1995cited by this paper
• Synaptic vesicular monoamine transporter expression: distribution and pharmacologic profile.

  1994cited by this paper
• Tardive dyskinesia.

  1993cited by this paper
• A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.

  1993cited by this paper
• Tardive tremor

  1992cited by this paper
• Neuroleptic malignant syndrome related to tetrabenazine introduction and haloperidol discontinuation in Huntington's disease.

  1992cited by this paper
• Clozapine treatment of psychiatric symptoms resistant to neuroleptic treatment in patients with Huntington's chorea

  1991cited by this paper
• [3H]Dihydrotetrabenazine, a new marker for the visualization of dopaminergic denervation in the rat striatum.

  1990cited by this paper
• [Huntington disease: tetrabenazine compared to haloperidol in the reduction of involuntary movements].

  1989cited by this paper
• Neuroleptically induced dystonia in Huntington's disease: a case report.

  1989cited by this paper
• Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias

  1988cited by this paper
• Depletion of monoamine transmitters by tetrabenazine in brain tissue in Huntington's disease.

  1988cited by this paper
• Motor, Behavioral and Pharmacologic Findings in Tourette's Syndrome

  1987cited by this paper
• Iatrogenic Parkinsonism in Huntington's Chorea

  1986cited by this paper
• A therapeutic approach to tardive dyskinesia.

  1985cited by this paper
• Blepharospasm and Meige syndrome: a review of diagnostic, aetiological and treatment approaches.

  1985cited by this paper
• Tetrabenazine-induced depletion of brain monoamines: characterization and interaction with selected antidepressants.

  1984cited by this paper
• Tetrabenazine (nitoman) therapy of chronic spontaneous oral dyskinesia

  1984cited by this paper
• Effect of tetrabenazine on tics and sleep of Gilles de la Tourette's syndrome

  1984cited by this paper
• Tolerance of tetrabenazine during long‐term treatment

  1983cited by this paper
• Tetrabenazine, an amine-depleting drug, also blocks dopamine receptors in rat brain.

  1983cited by this paper
• Tetrabenazine in the treatment of hyperkinetic movement disorders.

  1983cited by this paper
• Acido-basic properties of the catecholamine uptake inhibitors tetrabenazine and dihydrotetrabenazine.

  1982cited by this paper
• Treatment of hyperkinetic movement disorders with tetrabenazine: A double‐blind crossover study

  1982cited by this paper
• Tetrabenazine and movement disorders

  1981cited by this paper
• Determination of therapeutic plasma concentrations of tetrabenazine and an active metabolite by high-performance liquid chromatography.

  1981cited by this paper
• Neuroleptic Malignant syndrome caused by dopamine‐depleting drugs in a patient with Huntington disease

  1981cited by this paper
• Changes in prevalence, severity, and recovery in tardive dyskinesia with age.

  1980cited by this paper
• TETRABENAZINE FOR INVOLUNTARY MOVEMENT DISORDERS

  1979cited by this paper
• Tetrabenazine in the treatment of Huntington's chorea and other hyperkinetic movement disorders.

  1978cited by this paper
• Neurochemical changes following the administration of depleters of biogenic monoamines.

  1976cited by this paper
• Tetrabenazine in the treatment of Huntington's chorea.

  1976cited by this paper
• A double-blind trial of tetrabenazine, thiopropazate, and placebo in patients with chorea.

  1974cited by this paper
• Self‐poisoning with Tetrabenazine

  1972cited by this paper
• TETRABENAZINE IN THE TREATMENT OF EXTRAPYRAMIDAL DYSKINESIAS

  1972cited by this paper
• Self-poisoning with tetrabenazine.

  1972cited by this paper
• Treatment of involuntary movement disorders with tetrabenazine

  1972cited by this paper
• COMBINED NITOMAN®‐PIMOZIDE® TREATMENT OF HUNTINGTON'S CHOREA AND OTHER HYPERKINETIC SYNDROMES

  1970cited by this paper
• [THE TREATMENT OF EXTRAPYRAMIDAL HYPERKINESIAS WITH SPECIAL REFERENCE TO HUNTINGTON'S CHOREA].

  1964cited by this paper
• TETRABENAZINE (NITOMAN) IN THE TREATMENT OF PSYCHOSES. WITH A DISCUSSION ON THE CENTRAL MODE OF ACTION OF TETRABENAZINE AND RESERPINE.

  1963cited by this paper
• Benzoquinolizine Derivatives: a New Class of Monamine Decreasing Drugs With Psychotropic Action

  1962cited by this paper
• A trial of tetrabenazine ("Nitoman") in disturbed mentally subnormal patients.

  1962cited by this paper
• A comparison of tetrabenazine and chlorpromazine in chronic schizophrenia.

  1961cited by this paper
• Clinical comparison of tetrabenazine (Ro 1-9569), reserpine and placebo in chronic schizophrenics.

  1960cited by this paper
• Clinical comparison of tetrabenazine (Ro 1-9569), reserpine and placebo in chronic schizophrenics.

  1960cited by this paper
• [The treatment of chorea minor with the monoamine liberator "Nitoman"].

  1960cited by this paper
• Biochemical and pharmacological studies of RO 1-9569 (tetrabenazine), a nonindole tranquilizing agent with reserpine-like effects.

  1959cited by this paper
• Neuropsychiatric Disease and Treatment

  year unknowncited by this paper

• Genetic determinants of longitudinal behavioural trajectories in rare conditions: The case of fragile X syndrome.

  2025cites this paper
• Rare Diseases, Spotlighting Amyotrophic Lateral Sclerosis, Huntington’s Disease, and Myasthenia Gravis: Insights from Landscape Analysis of Current Research

  2025cites this paper
• Sida cordifolia is efficacious in models of Huntington’s disease by reducing ER stress

  2025cites this paper
• Berberine can be a Potential Therapeutic Agent in Treatment of Huntington's Disease: A Proposed Mechanistic Insight

  2025cites this paper
• Neurotransmitter recognition by human vesicular monoamine transporter 2

  2024cites this paper
• Emerging pharmacological approaches for Huntington's disease.

  2024cites this paper
• Heavy Metal Interactions with Neuroglia and Gut Microbiota: Implications for Huntington’s Disease

  2024cites this paper
• Drug repurposing for neurodegenerative diseases.

  2024cites this paper
• Neurotoxicology of dopamine: victim or assailant?

  2024cites this paper
• Nanoparticle-based Gene Therapy for Neurodegenerative Disorders.

  2024cites this paper
• Possibly Misleading Pharmaceutical Advertising On TV: A 2023 Ad for Ingrezza.

  2024cites this paper
• Amyloid-Induced Neurodegeneration: A Comprehensive Review through Aggregomics Perception of Proteins in Health and Pathology.

  2024cites this paper
• A Bioequivalence Comparison Between the Once‐Daily Extended‐Release Tablet and the Twice‐Daily Tablet Formulations of Deutetrabenazine at Steady State

  2024cites this paper
• Transport and inhibition mechanism for VMAT2-mediated synaptic vesicle loading of monoamines

  2024cites this paper
• Późne dyskinezy polekowe — rekomendacje grupy ekspertów: aktualizacja 2024

  2024cites this paper
• Protective Effects of Antcin H Isolated from Antrodia cinnamomea Against Neuroinflammation in Huntington’s Disease via NLRP3 Inflammasome Inhibition

  2024cites this paper
• Efficacy and Safety of Tetrabenazine in Reducing Chorea and Improving Motor Function in Individuals With Huntington's Disease: A Systematic Review

  2024cites this paper
• Neurodegenerative disease: New hopes and perspectives.

  2023cites this paper
• Mutant-Huntingtin Molecular Pathways Elucidate New Targets for Drug Repurposing

  2023cites this paper
• G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders

  2023influential citation
• Endocannabinoid Modulation in Neurodegenerative Diseases: In Pursuit of Certainty

  2022cites this paper
• Therapeutic drug repositioning with special emphasis on neurodegenerative diseases: Threats and issues

  2022cites this paper
• Integrative Meta-Analysis of Huntington’s Disease Transcriptome Landscape

  2022cites this paper
• Using a Caenorhabditis elegans Parkinson’s Disease Model to Assess Disease Progression and Therapy Efficiency

  2022cites this paper
• The effect of music on accuracy in the Stroop test

  2022cites this paper
• A Brief Review on the Role of Vesicular Monoamine Transporter2 Inhibitors in Hyperkinetic Movement Disorders

  2021cites this paper
• Synaptic pathology in Huntington’s disease: Beyond the corticostriatal pathway

  2021cites this paper
• Modulation of Huntington's disease in Drosophila.

  2021cites this paper
• MicroPET imaging of vesicular monoamine transporter 2 revealed the potentiation of (+)-dihydrotetrabenazine on MPTP-induced degeneration of dopaminergic neurons.

  2021cites this paper
• STRUCTURAL AND FUNCTIONAL CHARACTERIZATION OF LEUCINE-RICH REPEAT SYNAPTIC ADHESION MOLECULES

  2020cites this paper
• Discovery of sultam-containing small-molecule disruptors of the huntingtin–calmodulin protein–protein interaction

  2020cites this paper
• Pharmacokinetic and Metabolic Profile of Deutetrabenazine (TEV‐50717) Compared With Tetrabenazine in Healthy Volunteers

  2020cites this paper
• De-Novo Ligand Design against Mutated Huntington Gene by Ligand-Based Pharmacophore Modeling Approach.

  2020cites this paper
• Antidopaminergic treatment is associated with reduced chorea and irritability but impaired cognition in Huntington’s disease (Enroll-HD)

  2020cites this paper
• Therapeutics Advancement for Huntington Disease

  2019cites this paper
• Nanoparticles for drug delivery targeting neurodegeneration in brain and eye

  2019cites this paper
• VMAT2 Inhibitors and the Path to Ingrezza (Valbenazine).

  2018cites this paper
• Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review.

  2018cites this paper
• Inhibition of endocannabinoid degradation rectifies motivational and dopaminergic deficits in the Q175 mouse model of Huntington’s disease

  2018cites this paper
• Modificaciones moleculares aplicadas a la reserpina y la tetrabenazina para el diseño de fármacos duales para el tratamiento de la enfermedad de Huntington: evaluación por métodos quimioinformáticos y acoplamiento molecular

  2018cites this paper
• Old Drugs as New Treatments for Neurodegenerative Diseases

  2018cites this paper
• Advanced Chemometric Modeling Approaches for the Design of Multitarget Drugs Against Neurodegenerative Diseases

  2018cites this paper
• The therapeutic potential of cell identity reprogramming for the treatment of aging‐related neurodegenerative disorders

  2017cites this paper
• Characterization of Mice with Altered Dopamine Transporter and Vesicular Monoamine Transporter 2 Levels

  2017cites this paper
• The Role of RNF4 in Stripping Transcriptionally-Active Huntingtin

  2017cites this paper
• Comparison of Analytical Spectrophotometric Methods for the Determination of Tetrabenazine in Tablets

  2017cites this paper
• The Complexity of Clinical Huntington's Disease: Developments in Molecular Genetics, Neuropathology and Neuroimaging Biomarkers.

  2017cites this paper
• Protective Effect of Antioxidants on Neuronal Dysfunction and Plasticity in Huntington's Disease

  2017cites this paper
• Therapeutic advances in Huntington’s disease

  2016cites this paper
• RasGRP1 promotes amphetamine-induced motor behavior through a Rhes interaction network (“Rhesactome”) in the striatum

  2016cites this paper
• Compromised Dopaminergic Encoding of Reward Accompanying Suppressed Willingness to Overcome High Effort Costs Is a Prominent Prodromal Characteristic of the Q175 Mouse Model of Huntington's Disease

  2016cites this paper
• Tetrabenazine: Spotlight on Drug Review

  2016cites this paper
• Therapeutic Strategies for Huntington's Disease.

  2015influential citation
• Uneventful Recovery From a Suicide Attempt with Tetrabenazine: A Case Report

  2015cites this paper
• Tolerability and efficacy of the monoaminergic stabilizer (−)-OSU6162 (PNU-96391A) in Huntington’s disease: a double-blind cross-over study

  2014cites this paper
• Structural elucidation of two photolytic degradation products of tetrabenazine.

  2014cites this paper
• Co-administration of the Dopaminergic Stabilizer Pridopidine and Tetrabenazine in Rats

  2014cites this paper
• Treatment of Huntington’s Disease

  2013cites this paper
• The Role of Dopamine and Glutamate Modulation in Huntington Disease

  2013cites this paper
• The Pathophysiology and Pharmacological Treatment of Huntington Disease

  2013cites this paper
• Overexpressing Fragments of CREB-Binding Protein (CBP) to Block Transcriptional Dysregulation and Toxicity in Huntington's Disease

  2012cites this paper
• CHARACTERIZING THE FUNCTION OF HUNTINGTIN IN THE CELL STRESS RESPONSE AS A TARGET FOR DRUG DISCOVERY IN HUNTINGTON’S DISEASE

  2012cites this paper
• Clinical Assessment of the Effect of Tetrabenazine on Functional Scales in Huntington Disease: A Pilot Open Label Study

  2012cites this paper
• Quadriparesis and dysarthria due to tetrabenazine therapy in a child with rheumatic chorea

  2011cites this paper
• Degenerative Movement Disorders of the Central Nervous System

  2011cites this paper
• Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease

  2010cites this paper
• The therapeutic potential of G-protein coupled receptors in Huntington's disease.

  2010cites this paper
• Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease

  2010cites this paper
• Role of Tetrabenazine for Huntington's Disease-Associated Chorea

  2010cites this paper
• Tetrabenazine (Xenazine), An FDA-Approved Treatment Option For Huntington's Disease-Related Chorea.

  2008influential citation
• Neuromuscular blocking agents and skeletal muscle relaxants

  2007cites this paper